Alex Denner is the founding partner and chief investment officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. From 2006 to 2011, Denner served as a senior managing director at Icahn Capital, an entity through which Carl Icahn conducts his investment activities. Prior to that, he was a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Denner currently serves as a director of Biogen Inc., Bioverativ Inc. and The Medicines Company, all health care companies. He previously served as a director of the following health care companies:
- ARIAD Pharmaceuticals Inc., where he also served as chairman
- Amylin Pharmaceuticals Inc., VIVUS Inc.
- Enzon Pharmaceuticals Inc.
- ImClone Systems Inc., where he also served as chairman of the executive committee
Alex Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil and PhD degrees from Yale University. Denner has a strong background overseeing the operations, capital allocation and research and development of health care companies and evaluating corporate governance matters. He also has extensive experience as an investor, particularly with respect to health care companies and has broad health care industry knowledge.